Synthesis and Anti-tubercular Activity of 6-(4-Chloro/Methyl-phenyl)-4- Arylidene-4,5-dihydropyridazin-3(2H)-one Derivatives Against Mycobacterium tuberculosis
Two series of 6-(4-Cl-Phenyl)-4-arylidene-4,5-dihydropyridazin-3(2H)-one (3a-e) and 6- (4-CH3-Phenyl)-4-arylidene-4,5-dihydropyridazin-3(2H)-one derivatives (3f-j) were synthesized and evaluated as antitubercular agents against Mycobacterium tuberculosis H37Rv strain by using Microplate
Alamar Blue Assay (MABA) method. These compounds (3a-e & 3f-j) were synthesized from 6-(4-Cl-Phenyl)-4,5-dihydropyridazin-3(2H)-one (2a) and 6-(4-CH3-Phenyl)-4,5-dihydropyridazin- 3(2H)-one (2b) compounds by reacting with appropriate aldehydes respectively. All title compounds (3a-e &
3f-j) were characterized on the basis of IR, 1HNMR, mass spectral and elemental analysis data. All title compounds (3a-e & 3f-j) were used at 0.2µg/mL to 100µg/mL dose levels for antitubercular activity. Result showed that all the title compounds (3a-e & 3f-j) exhibited
less antitubercular activity as compared to the reference drugs streptomycin (MIC value of 6.25µg/mL) and pyrizinamide (MIC value of 3.125µg/mL), except compound 3e, which was equally effective as streptomycin but less effective than pyrazinamide.
Keywords: Pyridazinone; antitubercular agents; infectious disease; mycobacterium tuberculosis; spectral data; synthesis
Document Type: Research Article
Publication date: 01 July 2015
- Letters in Drug Design & Discovery publishes original letters on all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts. The journal is essential reading to all pharmaceutical scientists involved in research in drug design and discovery.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content